The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis

Future Oncol. 2017 Apr;13(9):843-857. doi: 10.2217/fon-2016-0420. Epub 2017 Jan 11.

Abstract

Aim: To review the predictive values of Ki-67 before neoadjuvant chemotherapy (NAC) for breast cancer patients.

Methods: PubMed and EMBASE were searched. Random-effect model meta-analysis was conducted using Revman software.

Results: High Ki-67 was associated with more pathological complete responses (pCRs) events (odds ratio: 3.10; 95% CI: 2.52-3.81; 53 studies, 10,848 patients) regardless of HR+, HER2+ and triple-negative breast cancer types, the definitions of pCR and cut-off points for Ki-67. Ki-67 could predict pCR in those who received anthracyclines plus taxanes, and anthracyclines only, and those from Asia and Europe.

Conclusion: High Ki-67 before NAC was a predictor for pCR in neoadjuvant setting for breast cancer patients.

Keywords: Ki-67; neoadjuvant chemotherapy; pathological complete response.

Publication types

  • Meta-Analysis
  • Review
  • Systematic Review

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Biomarkers, Tumor*
  • Breast Neoplasms / diagnosis*
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / metabolism*
  • Female
  • Humans
  • Ki-67 Antigen / metabolism*
  • Neoadjuvant Therapy
  • Odds Ratio
  • Prognosis
  • Publication Bias
  • Treatment Outcome

Substances

  • Biomarkers, Tumor
  • Ki-67 Antigen